GIP (3-42), human

Cat. No.:	HY-P2542
CAS No.:	1802086-25-4
Molecular Formula:	$C_{214}H_{324}N_{58}O_{63}S$
Molecular Weight:	4749.4
Sequence:	Glu-Gly-Thr-Phe-Ile-Ser-Asp-Tyr-Ser-Ile-Ala-Met-Asp-Lys-Ile-His-Gln-Gln-Asp-Phe-Val-Asn-Trp-Leu-Leu-Ala-Gln-Lys-Gly-Lys-Lys-Asn-Asp-Trp-Lys-His-Asn-Ile-Thr-Gln
Sequence Shortening:	EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ
Target:	Insulin Receptor
Pathway:	Protein Tyrosine Kinase/RTK
Storage:	Sealed storage, away from moisture and light, under nitrogen Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light, under nitrogen)

EGTFISDYSIAMDKIHQQDFVNWLLAQKGKKNDWKHNITQ

SOLVENT & SOLUBILITY

In Vitro

H_2O : 50 mg/mL (10.53 mM; Need ultrasonic)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	0.2106 mL	1.0528 mL	2.1055 mL
	5 mM	0.0421 mL	0.2106 mL	0.4211 mL
	10 mM	0.0211 mL	0.1053 mL	0.2106 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: PBS
   Solubility: 10 mg/mL (2.11 mM); Clear solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description

GIP (3-42), human acts as a glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist, moderating the insulin secreting and metabolic actions of GIP in vivo[1].

In Vitro

The incretin hormone GIP is rapidly degraded in the circulation by dipeptidyl peptidase IV (DPP IV) forming the N-terminally truncated peptide GIP(3-42)[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. V A Gault, et al. Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo. J Endocrinol. 2002 Nov;175(2):525-33.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA